Back to top
more

Arrowhead Pharmaceuticals (ARWR)

(Real Time Quote from BATS)

$22.14 USD

22.14
300,451

+0.27 (1.24%)

Updated Apr 26, 2024 02:51 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ekta Bagri headshot

Biotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates

by Ekta Bagri

Earnings and pipeline updates from Biogen (BIIB) and Arrowhead (ARWR) are they key highlights of the biotech sector.

Horizon's (HZNP) Q2 Earnings and Revenues Beat, Stock Up

by Zacks Equity Research

Horizon (HZNP) beats on both earnings and revenues in Q2. Sales soared on account of the relaunch of the thyroid eye disease drug Tepezza. As a result, stock rises.

Biotech Stock Roundup: Bristol-Myers' Updates, VCNX's Disappointing Data & More

by Zacks Equity Research

The biotech sector remains in focus with regulatory and other pipeline updates.

Sweta Killa headshot

Should First Trust Mid Cap Growth AlphaDEX ETF (FNY) Be on Your Investing Radar?

by Sweta Killa

Style Box ETF report for FNY

Arrowhead (ARWR) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

We expect Arrowhead (ARWR) to provide pipeline updates when it releases first-quarter fiscal 2020 results.

Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FNY

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Zacks Equity Research

Sector ETF report for PSCH

Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FNY

Sweta Killa headshot

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Sweta Killa

Sector ETF report for PSCH

Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FNY

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Zacks Equity Research

Sector ETF report for PSCH

Should First Trust Small Cap Growth AlphaDEX Fund (FYC) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FYC

Ekta Bagri headshot

4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics

by Ekta Bagri

We take a look at companies, which have been developing treatments for various diseases using RNAi technology.

J&J Strikes Deal with argenx to Co-Develop Cancer Antibody

by Zacks Equity Research

Johnson & Johnson (JNJ) inks a global deal with Europe's argenx to jointly develop and globally commercialize the latter's prospective antibody, cusatuzumab.

Arbutus (ABUS) Plunges on Disappointing HBV Pipeline Updates

by Zacks Equity Research

Arbutus Biopharma (ABUS) provides updates on its HBV development programs. However, uncertainty and early to mid-stage of development remains a concern.

    J&J Inks Deal With Arrowhead for Promising Liver Candidate

    by Zacks Equity Research

    Johnson & Johnson (JNJ) signs a licensing pact with Arrowhead to develop the latter's RNAi therapy candidate, ARO-HBV, for treating chronic hepatitis B viral infection. The deal is worth $3.7 billion.

      Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?

      by Zacks Equity Research

      Style Box ETF report for DWAS